Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Pfizer Inc., historical price multiples (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Price to earnings (P/E) 18.42 37.00 73.42 16.60 9.42 7.44 7.58 8.81 9.56 11.11 11.76 14.03 20.05 20.15 19.62
Price to operating profit (P/OP) 11.92 27.24 121.63 17.49 9.17 6.74 6.80 7.82 9.11 11.49 13.30 16.37 19.83 22.85 23.12
Price to sales (P/S) 2.32 2.60 3.00 2.86 2.61 2.51 2.58 2.32 2.37 2.63 2.77 3.00 3.18 4.04 4.78 4.84 4.50
Price to book value (P/BV) 1.68 1.70 1.92 1.74 1.75 1.80 2.04 2.14 2.48 2.83 3.21 3.37 3.35 3.69 3.78 3.27 2.98 3.10 3.31 3.16

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Pfizer Inc. P/S ratio decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Pfizer Inc. P/BV ratio decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.

Price to Earnings (P/E)

Pfizer Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
No. shares of common stock outstanding1 5,667,340,414 5,666,990,035 5,666,695,064 5,666,592,898 5,646,778,425 5,646,413,292 5,645,959,570 5,645,307,020 5,619,074,621 5,613,314,537 5,612,351,809 5,610,895,801 5,623,346,471 5,612,866,598 5,606,688,356 5,597,693,867 5,577,629,491 5,558,396,599 5,556,879,807 5,554,833,754
Selected Financial Data (US$)
Net income (loss) attributable to Pfizer Inc. common shareholders (in millions) 410 4,465 41 3,115 (3,369) (2,382) 2,327 5,543 4,994 8,608 9,906 7,864 3,393 8,146 5,563 4,877 1,303 1,469 3,489 3,355
Earnings per share (EPS)2 1.42 0.75 -0.46 -0.05 0.38 1.86 3.80 5.15 5.58 5.30 5.22 4.45 3.91 3.54 2.36 1.99 1.72 0.00 0.00 0.00
Share price1, 3 26.10 27.76 29.74 28.27 27.55 30.82 35.84 38.30 42.30 46.72 49.95 49.45 45.96 49.73 47.24 40.10 33.82 36.39 38.27 36.96
Valuation Ratio
P/E ratio4 18.42 37.00 73.42 16.60 9.42 7.44 7.58 8.81 9.56 11.11 11.76 14.03 20.05 20.15 19.62
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 79.59 69.16 62.04 48.26 63.84 38.27 30.55 34.43 22.62 19.16 19.44 21.64 22.07 27.34 30.62 39.63 40.17
Amgen Inc. 38.24 40.68 53.65 44.38 23.14 18.09 16.31 16.18 19.56 21.00 20.03 22.23 21.05 21.91 22.56 19.20 18.82
Bristol-Myers Squibb Co. 12.27 13.01 15.93 19.43 23.97 23.71 24.14 25.64 20.92
Danaher Corp. 38.12 48.49 45.39 42.59 39.09 24.76 29.99 25.00 25.65 26.65 32.73 32.15 29.94 38.81 37.87 39.26 44.49
Eli Lilly & Co. 77.63 96.05 109.42 120.94 135.24 110.43 76.21 65.16 50.08 55.53 51.05 45.29 40.66 40.07 40.34 28.77 31.95
Gilead Sciences Inc. 296.57 925.87 89.29 166.76 16.17 17.10 17.88 17.75 22.68 29.30 18.66 17.25 12.36 11.44 16.83 277.25 641.48
Johnson & Johnson 26.92 27.19 10.11 9.46 10.73 10.12 33.35 33.43 22.97 23.52 24.98 23.95 20.93 23.98 25.51 28.35 28.92
Merck & Co. Inc. 13.49 20.98 20.73 140.05 893.99 56.85 86.53 22.92 19.21 16.41 13.36 15.70 14.78 28.65 34.23 28.00 26.72
Regeneron Pharmaceuticals Inc. 17.76 19.79 27.88 26.78 25.99 22.35 19.48 19.77 19.68 14.98 11.67 9.15 8.37 9.96 10.38 13.27 15.09
Thermo Fisher Scientific Inc. 32.03 34.78 37.81 36.21 35.65 29.57 37.01 34.99 30.55 27.64 31.09 28.15 27.35 29.43 24.63 23.23 27.89
Vertex Pharmaceuticals Inc. 26.34 30.42 28.09 27.49 27.34 23.02 24.62 23.12 26.50 26.55 22.09 26.26 20.45 20.18

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Data adjusted for splits and stock dividends.

2 Q4 2024 Calculation
EPS = (Net income (loss) attributable to Pfizer Inc. common shareholdersQ4 2024 + Net income (loss) attributable to Pfizer Inc. common shareholdersQ3 2024 + Net income (loss) attributable to Pfizer Inc. common shareholdersQ2 2024 + Net income (loss) attributable to Pfizer Inc. common shareholdersQ1 2024) ÷ No. shares of common stock outstanding
= (410,000,000 + 4,465,000,000 + 41,000,000 + 3,115,000,000) ÷ 5,667,340,414 = 1.42

3 Closing price as at the filing date of Pfizer Inc. Quarterly or Annual Report.

4 Q4 2024 Calculation
P/E ratio = Share price ÷ EPS
= 26.10 ÷ 1.42 = 18.42

5 Click competitor name to see calculations.


Price to Operating Profit (P/OP)

Pfizer Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
No. shares of common stock outstanding1 5,667,340,414 5,666,990,035 5,666,695,064 5,666,592,898 5,646,778,425 5,646,413,292 5,645,959,570 5,645,307,020 5,619,074,621 5,613,314,537 5,612,351,809 5,610,895,801 5,623,346,471 5,612,866,598 5,606,688,356 5,597,693,867 5,577,629,491 5,558,396,599 5,556,879,807 5,554,833,754
Selected Financial Data (US$)
Operating income (loss) (in millions) 2,347 4,959 1,003 4,102 (4,289) (3,170) 2,194 6,544 4,381 8,943 12,219 9,401 2,991 6,147 5,606 4,689 613 2,448 2,072 3,027
Operating profit per share2 2.19 1.02 -0.42 -0.21 0.23 1.76 3.91 5.68 6.22 5.98 5.48 4.30 3.46 3.04 2.38 1.75 1.46 0.00 0.00 0.00
Share price1, 3 26.10 27.76 29.74 28.27 27.55 30.82 35.84 38.30 42.30 46.72 49.95 49.45 45.96 49.73 47.24 40.10 33.82 36.39 38.27 36.96
Valuation Ratio
P/OP ratio4 11.92 27.24 121.63 17.49 9.17 6.74 6.80 7.82 9.11 11.49 13.30 16.37 19.83 22.85 23.12
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 37.26 25.63 26.99 22.62 24.34 16.55 15.26 16.15 14.78 14.52 14.12 14.57 14.21 12.41 13.12 17.23 16.32
Amgen Inc. 21.55 27.68 27.12 23.97 19.69 15.45 13.71 14.25 13.40 14.89 14.08 15.88 16.24 16.73 17.48 15.26 14.96
Bristol-Myers Squibb Co. 13.53 14.14 16.24 17.09 18.29 17.79 18.62 20.32 19.84
Danaher Corp. 30.56 39.52 38.14 37.52 35.64 23.61 27.01 21.31 20.97 20.71 25.91 26.48 25.14 32.12 30.83 32.62 36.91
Eli Lilly & Co. 63.73 79.30 88.66 99.34 109.75 93.27 69.42 59.60 43.88 46.48 39.20 36.49 35.70 37.21 42.01 31.17 32.66
Gilead Sciences Inc. 85.65 143.05 36.80 51.26 12.05 12.16 11.57 11.21 14.21 16.27 11.02 10.78 7.76 7.27 8.88 18.31 19.38
Johnson & Johnson 18.20 18.65 17.54 16.96 17.78 15.69 18.91 18.26 17.62 19.64 20.45 21.06 18.68 18.99 20.14 21.12 21.84
Merck & Co. Inc. 11.60 18.67 18.41 75.94 138.56 33.75 44.67 18.53 15.55 13.85 11.72 14.29 15.39 30.71 38.03 30.14 23.89
Regeneron Pharmaceuticals Inc. 19.63 23.18 30.86 26.82 25.39 21.13 19.32 18.68 18.01 12.91 9.68 7.98 7.55 9.32 9.65 13.32 14.82
Thermo Fisher Scientific Inc. 27.65 29.74 32.66 31.40 31.16 25.59 31.55 29.54 25.30 21.43 23.99 21.84 21.07 23.87 19.77 18.53 22.81
Vertex Pharmaceuticals Inc. 25.25 28.74 25.14 23.33 22.03 17.75 19.41 18.11 22.13 22.35 18.14 23.06 18.68 19.16

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Data adjusted for splits and stock dividends.

2 Q4 2024 Calculation
Operating profit per share = (Operating income (loss)Q4 2024 + Operating income (loss)Q3 2024 + Operating income (loss)Q2 2024 + Operating income (loss)Q1 2024) ÷ No. shares of common stock outstanding
= (2,347,000,000 + 4,959,000,000 + 1,003,000,000 + 4,102,000,000) ÷ 5,667,340,414 = 2.19

3 Closing price as at the filing date of Pfizer Inc. Quarterly or Annual Report.

4 Q4 2024 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 26.10 ÷ 2.19 = 11.92

5 Click competitor name to see calculations.


Price to Sales (P/S)

Pfizer Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
No. shares of common stock outstanding1 5,667,340,414 5,666,990,035 5,666,695,064 5,666,592,898 5,646,778,425 5,646,413,292 5,645,959,570 5,645,307,020 5,619,074,621 5,613,314,537 5,612,351,809 5,610,895,801 5,623,346,471 5,612,866,598 5,606,688,356 5,597,693,867 5,577,629,491 5,558,396,599 5,556,879,807 5,554,833,754
Selected Financial Data (US$)
Revenues (in millions) 17,763 17,702 13,283 14,879 14,568 13,492 13,007 18,486 24,289 22,638 27,742 25,661 23,838 24,035 18,899 14,516 11,684 10,277 9,864 10,083
Sales per share2 11.23 10.66 9.92 9.87 10.55 12.27 13.89 16.50 17.86 17.79 18.05 16.47 14.46 12.32 9.88 8.28 7.51 0.00 0.00 0.00
Share price1, 3 26.10 27.76 29.74 28.27 27.55 30.82 35.84 38.30 42.30 46.72 49.95 49.45 45.96 49.73 47.24 40.10 33.82 36.39 38.27 36.96
Valuation Ratio
P/S ratio4 2.32 2.60 3.00 2.86 2.61 2.51 2.58 2.32 2.37 2.63 2.77 3.00 3.18 4.04 4.78 4.84 4.50
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 6.04 6.38 6.02 5.32 5.72 4.52 4.74 4.60 4.61 4.44 4.28 4.76 4.53 3.73 3.80 4.07 4.05
Amgen Inc. 4.88 5.53 5.68 5.93 5.78 5.34 5.14 5.14 5.17 5.85 5.35 5.21 5.10 5.04 5.37 5.68 5.64
Bristol-Myers Squibb Co. 2.36 2.38 2.20 1.99 2.19 2.40 2.81 3.10 3.29 3.39 3.39 3.41 3.16 2.85 3.44 3.28 3.16
Danaher Corp. 6.23 7.95 8.10 7.90 7.76 5.63 6.77 5.76 5.79 5.66 6.59 6.68 6.37 7.91 7.72 7.27 7.01
Eli Lilly & Co. 18.25 19.67 20.64 20.66 20.77 17.18 16.78 13.38 10.96 11.46 9.99 9.47 8.01 8.62 9.16 6.88 8.06
Gilead Sciences Inc. 4.98 4.18 3.41 2.97 3.40 3.69 3.61 3.70 3.86 3.64 2.84 2.86 2.85 3.11 3.30 3.31 3.24
Johnson & Johnson 4.26 4.55 4.44 4.25 4.43 4.01 4.84 4.60 4.34 4.69 4.80 5.00 4.66 4.69 5.08 5.09 5.15
Merck & Co. Inc. 3.60 4.03 4.56 5.26 5.43 4.42 4.62 5.16 4.71 4.25 3.87 4.12 3.96 4.32 4.05 4.23 3.93
Regeneron Pharmaceuticals Inc. 5.52 6.65 8.93 7.89 7.84 6.81 6.61 6.69 7.01 5.87 4.66 4.40 4.20 5.14 5.20 5.78 6.24
Thermo Fisher Scientific Inc. 4.73 5.04 5.55 5.14 4.99 4.05 4.87 4.81 4.73 4.40 5.40 5.20 5.39 6.45 5.54 5.13 5.52
Vertex Pharmaceuticals Inc. 10.78 12.12 12.35 10.39 11.16 10.10 9.73 9.68 8.56 9.26 8.85 8.17 8.21 6.74 7.82 8.81 8.82

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Data adjusted for splits and stock dividends.

2 Q4 2024 Calculation
Sales per share = (RevenuesQ4 2024 + RevenuesQ3 2024 + RevenuesQ2 2024 + RevenuesQ1 2024) ÷ No. shares of common stock outstanding
= (17,763,000,000 + 17,702,000,000 + 13,283,000,000 + 14,879,000,000) ÷ 5,667,340,414 = 11.23

3 Closing price as at the filing date of Pfizer Inc. Quarterly or Annual Report.

4 Q4 2024 Calculation
P/S ratio = Share price ÷ Sales per share
= 26.10 ÷ 11.23 = 2.32

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Pfizer Inc. P/S ratio decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.

Price to Book Value (P/BV)

Pfizer Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
No. shares of common stock outstanding1 5,667,340,414 5,666,990,035 5,666,695,064 5,666,592,898 5,646,778,425 5,646,413,292 5,645,959,570 5,645,307,020 5,619,074,621 5,613,314,537 5,612,351,809 5,610,895,801 5,623,346,471 5,612,866,598 5,606,688,356 5,597,693,867 5,577,629,491 5,558,396,599 5,556,879,807 5,554,833,754
Selected Financial Data (US$)
Total Pfizer Inc. shareholders’ equity (in millions) 88,203 92,286 87,700 92,282 89,014 96,934 99,019 100,970 95,661 92,631 87,208 82,424 77,201 75,691 70,042 68,620 63,238 65,259 64,336 65,026
Book value per share (BVPS)2 15.56 16.28 15.48 16.29 15.76 17.17 17.54 17.89 17.02 16.50 15.54 14.69 13.73 13.49 12.49 12.26 11.34 11.74 11.58 11.71
Share price1, 3 26.10 27.76 29.74 28.27 27.55 30.82 35.84 38.30 42.30 46.72 49.95 49.45 45.96 49.73 47.24 40.10 33.82 36.39 38.27 36.96
Valuation Ratio
P/BV ratio4 1.68 1.70 1.92 1.74 1.75 1.80 2.04 2.14 2.48 2.83 3.21 3.37 3.35 3.69 3.78 3.27 2.98 3.10 3.31 3.16
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 102.40 58.73 48.87 36.12 29.97 20.61 20.62 19.68 15.52 16.06 16.76 16.59 16.53 15.20 16.23 14.91 14.18 10.93 11.31
Amgen Inc. 26.61 22.86 28.34 33.25 24.94 17.87 19.19 23.95 35.01 39.30 54.46 138.87 18.51 14.95 15.72 14.57 14.53 11.57 13.67 14.33
Bristol-Myers Squibb Co. 6.98 6.60 6.01 5.49 3.35 3.72 3.97 4.46 4.88 4.85 4.90 5.07 4.07 3.48 4.15 3.73 3.55 2.87 2.82 2.77
Danaher Corp. 3.00 3.68 3.82 3.51 3.47 2.78 3.65 3.33 3.64 3.77 4.36 4.36 4.16 5.11 4.82 4.46 3.93 4.38 3.90 3.68
Eli Lilly & Co. 57.93 56.45 59.24 57.94 65.80 49.10 44.75 33.11 29.36 33.27 34.00 29.75 25.28 30.85 38.00 25.41 35.07 26.02 35.12 47.73
Gilead Sciences Inc. 7.36 6.36 5.15 4.61 4.01 4.50 4.63 4.72 4.90 4.63 3.82 3.91 3.65 3.94 4.41 4.40 4.33 4.30 4.79 4.40
Johnson & Johnson 5.30 5.69 5.37 5.20 5.48 4.92 5.79 6.00 5.37 6.04 6.01 6.36 5.90 6.10 6.51 6.51 6.72 5.93 6.19 6.46
Merck & Co. Inc. 4.99 5.73 6.53 8.00 8.68 6.35 6.96 6.38 6.07 5.63 5.12 5.44 5.05 5.76 5.73 7.30 7.46 6.97 7.47 7.43
Regeneron Pharmaceuticals Inc. 2.67 3.14 4.27 3.83 3.96 3.58 3.49 3.52 3.77 3.75 3.21 3.65 3.60 4.04 4.26 4.44 4.81 6.21 7.34 5.33
Thermo Fisher Scientific Inc. 4.09 4.36 4.96 4.80 4.57 3.88 4.84 4.99 4.83 4.46 5.47 5.23 5.18 6.51 5.75 5.25 5.15 5.89 5.48 4.56
Vertex Pharmaceuticals Inc. 7.24 8.24 8.64 5.71 6.26 5.90 5.98 6.18 5.50 6.18 6.19 5.95 6.16 5.04 5.69 6.29 6.30 6.66 9.42 10.23

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Data adjusted for splits and stock dividends.

2 Q4 2024 Calculation
BVPS = Total Pfizer Inc. shareholders’ equity ÷ No. shares of common stock outstanding
= 88,203,000,000 ÷ 5,667,340,414 = 15.56

3 Closing price as at the filing date of Pfizer Inc. Quarterly or Annual Report.

4 Q4 2024 Calculation
P/BV ratio = Share price ÷ BVPS
= 26.10 ÷ 15.56 = 1.68

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Pfizer Inc. P/BV ratio decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.